A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Study Summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.

Conditions

Chronic Kidney Failure End-Stage Renal Disease Renal Impairment

Interventions / Drugs

MK-2828

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment24 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.206447+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.